Pharmaceuticals
Nippon Express (India) Newly Acquires GDP Certification at Three Locations
TOKYO, July 8, 2021 /PRNewswire/ -- Nippon Express (India) Private Limited (hereinafter "NE India"), a local subsidiary of Nippon Express Co., Ltd., obtained Good Distribution Practice (GDP) certification in April for its temperature-controlled hubs inDelhi, Mumbai and Ahmedabad, evidencing the ...
2021-07-08 15:00
1095
BioShin Expands Senior Leadership Team: Sarah Lu Joins BioShin as Chief Medical Officer, Mary Ma Joins BioShin as Chief Commercial Officer
SHANGHAI, July 8, 2021 /PRNewswire/ -- BioShin Limited today announced the appointment of Dr.Zhihong (Sarah) Lu as Chief Medical Officer and Dr. Ma (Mary) Li as Chief Commercial Officer. Sarah will play a critical role in BioShin's clinical development of pipeline products inAsia-Pacific markets,...
2021-07-08 12:01
2232
Harbour BioMed Reports Positive Topline Results from Phase 2 Trial of Batoclimab (HBM9161) in Generalized Myasthenia Gravis
* Both batoclimab 340 mg and 680 mg treatment groups demonstrated rapid, substantial and persistent clinical improvement over placebo * Favorable safety and tolerability profile with no serious adverse events (SAEs) and no adverse events (AEs) leading to discontinuation * Strong IgG reductio...
2021-07-06 21:06
18032
Bionomics Initiates Phase 2b ATTUNE Study of BNC210 in PTSD
ADELAIDE, Australia, July 6, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (Bionomics or Company), a global, clinical stage biopharmaceutical company, is pleased to announce that it has initiated a Phase2b trial (the ATTUNE Study) to evaluate the tablet formulation of BNC210 in p...
2021-07-06 18:00
17071
Transcenta Provides Program Update for Anti-Claudin18.2 Monoclonal Antibody TST001 and Reports Promising Early Anti-Tumor Responses in Patients with Gastric Cancer
SUZHOU, China, July 2, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announces that promising anti-tumor response...
2021-07-02 21:02
2812
I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio
* First patient dosed in U.S. phase 1 clinical trial of TJ-CD4B/ABL111 in patients with advanced or metastatic solid tumors * China sites to join the dose expansion part of the study to accelerate TJ- CD4B/ABL111 development * Results of TJ-L14B/ABL503 preclinical studies accepted for publica...
2021-07-01 20:00
13276
Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer's and Parkinson's
MELBOURNE, Australia and SAN FRANCISCO, July 1, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the granting of a new composition of matter patent by the United States Patent and Trademark Office (USPTO). The patent secures a ...
2021-07-01 19:50
13368
Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs
SYDNEY, June 30, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update on recent progress with its two pipeline assets, paxalisib and EVT801. Key Points * GBM AGILE pivotal study of paxalisib is...
2021-06-30 22:00
30329
I-Mab Honored with Top Rankings by Institutional Investor
SHANGHAI and GAITHERSBURG, Md., June 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it was ranked among the top companies by leading gl...
2021-06-30 20:00
12659
Akeso Awarded as 2021 "Most Honored Company" by Institutional Investor
HONG KONG, June 30, 2021 /PRNewswire/ -- Akeso, Inc. ("Akeso" or the "Company", stock code: 9926.HK) is pleased to announce today that, Akesohas been awarded as "Most Honored Company" in the "2021 All-Asia Executive Team" survey published byInstitutional Investor, and has been ranked top 3 in all...
2021-06-30 16:00
13333
OnCusp Therapeutics Commences Operations to Advance Innovative Oncology Therapies
NEW YORK, June 29, 2021 /PRNewswire/ -- OnCusp Therapeutics (or "OnCusp"), a global biopharmaceutical company focused on translating cutting-edge research assets into innovative oncology therapeutics, announced that it has officially commenced operations both inNew York and Shanghai. OnCusp succ...
2021-06-30 09:29
1501
I-Mab Announces Upcoming Participation at July Conference
SHANGHAI and GAITHERSBURG, Md., June 29, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conference in July. D...
2021-06-29 20:00
8361
Lianhua Qingwen Granted Market Access as Medicine in Ukraine: Yiling Pharmaceutical
SHIJIAZHUANG, China, June 29, 2021 /PRNewswire/ -- Yiling Pharmaceutical disclosed in a statement on Monday that it had received the medicine registration document for Lianhua Qingwen Capsules from the Ministry of Health ofUkraine. As the leading product of Yiling Pharmaceutical, Lianhua Qingwen...
2021-06-29 16:41
2574
First in China! Neurophth announced the first patient has been dosed in G.O.L.D. clinical trial for the gene therapy treatment of LHON
* Novel and one-time intravitreal injection of ND4 gene therapy for the treatment of LHON potentially restored vision * Phase I/II/III clinical trial expected to enroll patients with LHON due to ND4 mutation WUHAN, China and SAN DIEGO, June 28, 2021 /PRNewswire/ -- Neurophth Biotechnology Ltd...
2021-06-28 21:33
1665
ILIAS Biologics Inc. demonstrated the therapeutic effect of anti-inflammatory exosomes for ischemia-reperfusion-induced acute kidney injury
DAEJEON, South Korea, June 28, 2021 /PRNewswire/ -- Anti-inflammatory exosomes could have a place in treating acute kidney injury (AKI) caused by ischemia repercussion injury (IRI), according to a study done by ILIAS Biologics, Inc. in collaboration withYonsei University of Seoul, South Korea. ...
2021-06-28 20:00
1504
InnoCare Announces Breakthrough Therapy Designation of Orelabrutinib by US FDA for Treatment of R/R MCL
BEIJING, June 28, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib for the trea...
2021-06-28 16:02
10514
Sanyou Biopharmaceuticals completes series B financing and secures its leading role in innovative antibody drug discovery
SHANGHAI, June 26, 2021 /PRNewswire/ -- Sanyou Biopharmaceutical (Shanghai) Co., Ltd. (hereafter referred to as "Sanyou Bio" or "the Company"), a leading company in innovative antibody drug discovery, announced the closing of series B financing. This financing round was co-led by LH Ventures and ...
2021-06-26 23:00
3555
I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus
SHANGHAI and GAITHERSBURG, Md., June 25, 2021 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of the China N...
2021-06-25 20:00
16389
InnoCare Announces Approval of Initiation of Phase 1 Clinical Trial of RTK Inhibitor ICP-033 in China
BEIJING, June 25, 2021 /PRNewswire/ -- InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today thatChina's National Medical Products Administration (NMPA) has approved the initiation of a Phase I clinical trial of ICP-033, the Compan...
2021-06-25 19:04
16227
Zuellig Pharma Selects CYFIRMA to Elevate Cyber-intelligence Capabilities and Strengthen Cybersecurity Posture
SINGAPORE, June 25, 2021 /PRNewswire/ -- CYFIRMA, a threat discovery and
cyber-intelligence platform company, funded by Goldman Sachs, Zodius Capital
and Z3Partners, today announced thatZuellig Pharma
2021-06-25 12:57
2050
Week's Top Stories
Most Reposted
Supported by the Luxembourg Government, The Luxembourg House of Financial Technology (LHoFT) and the Asian Development Bank (ADB) Announce the 2nd Edition of Catapult | SE Asia 2025
[Picked up by 313 media titles]
2025-01-22 15:38
Blackpanda Recognized with Frost & Sullivan's Asia Pacific Company of the Year Award for Incident Response Excellence
[Picked up by 302 media titles]
2025-01-23 09:00
Agoda Expands Its Eco Deals Program Pledging Up to $1.5 Million to Fund Critical Conservation Projects Across 10 Asian Markets in Partnership with WWF
[Picked up by 292 media titles]
2025-01-23 09:00
Sephora Unveils Its First Film, "Beauty & Belonging" Celebrating Diversity and Authenticity
[Picked up by 288 media titles]
2025-01-24 08:00
Star-Studded Sponsor Line-up Takes Centre Court at the Singapore Tennis Open 2025
[Picked up by 287 media titles]
2025-01-28 10:49
Most Read
dss⁺ Announces Strategic Changes to Executive Leadership Team in Asia Pacific Accelerating growth and impact for high-hazard industries in the region
2025-01-21 16:00
7907
Supported by the Luxembourg Government, The Luxembourg House of Financial Technology (LHoFT) and the Asian Development Bank (ADB) Announce the 2nd Edition of Catapult | SE Asia 2025
2025-01-22 15:38
7147
BRI UMKM EXPO(RT) 2025 Returns: Showcasing Local Products to the World
2025-01-25 15:38
6216
